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Background
e past three decades of studies have unveiled some of 
the genetic underpinnings of human disease. For complex 
diseases, those with obscure genetic roots, discoveries 
have accelerated recently owing to a bloom of genome-
wide association studies (GWASs) [1]. Nevertheless, even 
for the most successful cases (such as inflammatory and 
ulcerative bowel disease [2,3]), discoveries account for 
only a fraction, often small, of the disease’s heritability. 
ese yet to be discovered genetic variants comprise the 
‘missing heritability’ or the genetic ‘dark matter’ for 
disease.
State of dark matter
Heritability, the proportion of trait variability explained 
by genetic factors, has two somewhat different meanings. 
Narrow-sense heritability involves only the additive 
effects of genes. Broad-sense heritability involves both 
additive and non-additive effects. e difference between 
the two makes a difference when hunting for dark matter. 
If genetic variation were all to act additively, the best 
predictor of an offspring’s trait value would be the 
average of his/her parents’ values. Human height is an 
excellent example, after adjusting for gender. Hunting for 
dark matter for a trait such as human height will be more 
straightforward than for a disease such as schizophrenia, 
for which the evidence for substantial gene-gene inter-
action is compelling [4]. Yet when researchers refer to 
heritability of human height, they implicitly mean 
narrow-sense heritability; for schizophrenia, it is 
heritability in a much broader sense.
Why should we care about the genetic basis of disease? 
Greater understanding of the genetics equals greater 
understanding of molecular etiology and, with it, 
eventually more cogent treatments. However, the origins 
of some human diseases, especially those of the mind, 
can be mysterious. For diseases of the mind, few environ-
mental or genetic risk factors are understood; instead the 
hope is that identified genetic factors will lead to a subtler 
understanding of why diseases such as schizophrenia 
arise and how they can be treated effectively. Even for 
cardiovascular disease, for which environmental risk 
factors are well characterized, new insights into its 
genetics could produce more targeted treatment. is 
leads to the other expectation - that greater genetic 
knowledge will pave the way for ‘personalized’ medicine. 
e rapid technological advances in genomics will soon 
make it feasible to sequence whole genomes at relatively 
low cost. e idea that each individual will have 
meaningful sequence variation in their medical records 
and will have interventions tailored to their risk profile 
and likely treatment response is quite appealing. e goal 
of personalized medicine, however, is hindered because 
so much molecular etiology remains in the dark.
One way to explain more of the dark matter is to 
develop more efficient ways to use existing data. 
Naukkarinen et al. [5] develop an innovative approach 
that integrates gene expression and genotype data. ey 
apply these ideas to a GWAS of obesity, as measured by 
body mass index (BMI). Studies estimate BMI’s 
heritability at 45 to 85%, but identified genetic variants 
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explain about 1% of the total variance [6]. To discover 
more variants, the authors [5] examined gene expression 
of adipose tissue in a sample of monozygotic (MZ) twins 
discordant for BMI and in a sample of unrelated 
individuals. Because MZ twins are genetically identical, 
or nearly so, the authors reasoned that genes showing 
expression differences between twins are ‘reactive’ genes 
with differences that are due to regulatory or epigenetic 
changes in response to environmental factors. By 
contrast, genes uncovered in unrelated individuals are a 
combination of reactive and genetically ‘causal’ genes. By 
contrasting results from the unrelated sample and 
discordant MZ twins, the authors identified 27 causal 
genes that were differentially regulated. They then tested 
197 single nucleotide polymorphisms (SNPs) falling in 
and around these genes in a sample of 21,000 subjects. 
They discovered a significant excess of small P-values in 
this set of SNPs. Neither the set of SNPs defined by 
reactive genes nor the individual SNPs in the reactive set 
were associated with BMI. Notably, this work identifies a 
new gene, F13A1, which encodes the coagulation factor 
XIII A chain, with variation that affects BMI. This gene 
has also been identified by meta-analysis of 12 studies of 
venous thromboembolism [7]. Obesity is well known to 
predispose to vein thromboses; however, the study of 
Naukkarinen et al. [5] reveals a potential biological path-
way for the relationship between obesity, thrombosis and 
cardiovascular risk.
The methods advanced by Naukkarinen and colleagues 
[5] require discordant MZ twins, which were available for 
BMI. This experimental design could prove highly infor-
ma tive for similar quantitative traits, for which extremes 
are easily identified and by which the pathology or 
phenotype of interest is defined. For some diseases, 
especially diseases of the brain, quantitative traits that 
map precisely onto risk are not yet available. In addition, 
because reactive genes are environment-dependent, 
successful implementation of this design might require a 
sample exposed to a homogeneous environment, limiting 
its generality. Regardless, this study shows how inno-
vative research can cast more light on dark matter. 
Moreover, the study design could also inform us about 
pathways of correlated gene expression and how much 
these correlations are influenced by genetic and 
environmental variation.
Many other methods and designs are available to 
illuminate dark matter [8-15]. One appealing approach 
teams gene-expression results with genome-wide asso-
cia tion data to produce targeted hypothesis tests [8]. One 
possibility is to organize tests by expression quantitative 
trait loci affecting genes in pathways meaningful for the 
disease. Statistical methods for targeted testing are 
available, whether on the basis of prior information of the 
likelihood of an association between a SNP and the 
phenotype or on the basis of plausible disease pathways 
[9,10]. Genetic variants with parental origin effects, or 
whose effects depend on the parent from whom they 
were inherited, could be part of the dark matter; methods 
are now available to determine the parental origin of 
alleles and haplotypes even in the absence of genotyped 
parents [13]. Studies of copy number variants and their 
inheritance in families could also reveal insight into 
plausible biological pathways for disease [14,15]. It is also 
safe to say that rare variants account for some of the dark 
matter [16], possibly the majority of it in some cases. 
Next-generation sequencing promises to fill some of our 
void in knowledge by identifying more penetrant but 
rarer variants.
Other approaches are less illuminating. Let’s reconsider 
human height. We know numerous rare variants and 
about 50 common variants that have an impact on height. 
Thus far, known genetics account for roughly 5% of the 
variance. Using many SNPs from GWAS analysis that are 
not significantly associated with height, Yang et al. [17] 
estimated the proportion of variance in height explained 
by SNPs as 0.45 and even got close to the heritability 
estimate of 0.84 after correcting for incomplete linkage 
disequilibrium between SNPs genotyped and causal 
variants. In spirit, this approach [17] is similar to the 
allele score method [18], which seeks a predictive model 
for disease status on the basis of thousands of SNPs with 
modest evidence for association. If their results are 
correct, both studies [17,18] suggest that the effects of 
SNPs are small and will be difficult or impossible to 
detect from simple analyses of GWASs, at least for 
current sample sizes [19]. These intriguing approaches 
have some drawbacks: they shed no new light on the 
molecular etiology of phenotype; and inherent in the 
calculations are assumptions that could prove difficult to 
validate.
We all recognize the hidden biases that inflate estimates 
of heritability. There are other complex pathways for the 
transmission of a phenotype across generations without 
the transmission of a specific common or rare variant, 
namely through epigenetic factors that can result in the 
inheritance of gene expression patterns without an 
alteration of the DNA sequence [20]. Gene-environment 
interactions could also affect the estimates of heritability 
and when they are in play, they can explain as much of 
the variance in the phenotype as genetic factors [21].
Conclusions
Concerted effort will almost surely be required to under-
stand the genetic architecture of most complex diseases. 
Naukkarinen et al.’s [5] novel study design illustrates the 
impact that concerted effort can have in advancing our 
knowledge of the genetic etiology of such diseases. There 
remains ample room for novel analytic methods and 
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study designs to shed light on the genetic dark matter of 
disease. It is entirely possible, 10 years hence, that we will 
realize that much of the missing heritability was hiding in 
plain sight in common variants.
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